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MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066)
Shows Differential Antitumor Effects in Non-small Cell Lung
Cancer According to MET Alterations
Junko Tanizaki, MD, Isamu Okamoto, MD, PhD, Kunio Okamoto, MD, PhD,
Ken Takezawa, MD, PhD, Kiyoko Kuwata, PhD, Haruka Yamaguchi, PhD,
and Kazuhiko Nakagawa, MD, PhD
Introduction: Tyrosine kinase inhibitors (TKIs) targeted to MET
are undergoing clinical trials in patients with solid tumors, but the
precise mechanism of the antitumor activity of these drugs remains
unclear. We examined the antitumor action of the MET-TKI crizo-
tinib (PF-02341066) in lung cancer cells that are positive or negative
for MET amplification or mutation.
Methods: The antitumor action of crizotinib was evaluated on the
basis of signal transduction, cell proliferation, apoptosis, and pro-
gression of tumor xenografts.
Results: Inhibition of MET signaling by crizotinib or by RNA
interference-mediated MET depletion resulted in the induction of
apoptosis accompanied by inhibition of AKT and extracellular
signal-regulated kinase phosphorylation in lung cancer cells with
MET amplification but not in cells with a MET mutation or in those
without amplification or mutation ofMET. These results suggest that
MET signaling is essential for the survival of cells with MET
amplification but not for that of cells without this genetic change,
including those with a MET mutation. Crizotinib up-regulated the
expression of BIM, a proapoptotic member of the Bcl-2 family, and
down-regulated that of survivin, a member of the inhibitor of
apoptosis protein family, in cells with MET amplification. Forced
depletion of BIM and expression of survivin each inhibited crizo-
tinib-induced apoptosis, suggesting that both up-regulation of BIM
and down-regulation of survivin contribute to the proapoptotic effect
of crizotinib.
Conclusions: Crizotinib shows a marked antitumor action in MET
amplification-positive lung cancer cells but not in cells without MET
amplification, including those with a MET mutation.
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Activation of protein tyrosine kinases (PTKs) plays a keyrole in oncogenesis, as exemplified by the role of the
BCR-ABL fusion gene in chronic myeloid leukemia and by
that of epidermal growth factor receptor (EGFR) gene muta-
tion and the EML4-ALK fusion gene in non-small cell lung
cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) that tar-
get activated PTKs have exhibited marked therapeutic effi-
cacy in patients with these specific molecular alterations.1–5
The identification of other target kinases or kinase gene
alterations would thus be expected to facilitate the develop-
ment of new molecularly targeted therapies.
Lung cancer is the leading cause of cancer death world-
wide. Despite the successful development of EGFR- or
EML4-ALK-targeted TKIs, treatment options remain limited
for patients with advanced lung cancer, making the identifi-
cation of new therapeutic targets an important goal. The
tyrosine kinase MET is one such potential therapeutic target.
Amplification of MET occurs in 5% of lung cancer
cases,6–9 and MET mutations have recently been detected in
10% of patients with this condition.10,11 Nevertheless, the
relationship between the efficacy of MET-TKIs and MET
status, such as amplification or mutation, has not been well
established. We have, therefore, now investigated the effects
of the MET-TKI crizotinib (PF-02341066),12,13 which is
currently undergoing clinical studies, on cell survival and
signal transduction in lung cancer cells with or without
amplification or mutation of MET. We further examined the
molecular mechanism underlying the antitumor action of this
agent.
MATERIALS AND METHODS
Cell Culture and Reagents
The human NSCLC cell lines H1993, H2122, H1437,
A549, H1299, PC9, HCC827, and H596 were obtained from
American Type Culture Collection (Manassas, VA). The
human NSCLC cell line EBC-1 was obtained from the Health
Science Research Resources Bank (Tokyo, Japan). The hu-
man NSCLC cell line H3122 was obtained as described
previously.14 All cells were maintained under a humidified
atmosphere of 5% CO2 at 37°C in RPMI 1640 medium
(Sigma, St. Louis, MO) supplemented with 10% fetal bovine
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serum. Crizotinib was kindly provided by Pfizer Global
Research & Development (Groton, CT). EBC-1 and H1993
cell lines were previously shown to manifest high-level am-
plification of MET (copy number, 10).15 Sequencing of all
21 coding exons of MET also previously revealed that H2122
cells contain an N375S mutation and that H1437 and H596
cells harbor a deletion of exon 14 of this gene.10,11
Growth Inhibition Assay In Vitro
Cells were plated in 96-well flat-bottomed plates and
cultured for 24 hours before exposure to various concentra-
tions of crizotinib for 72 hours. Cell viability was then
assessed with the use of a Cell Titer-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI). Absorbance values
were expressed as a percentage of that for untreated cells, and
the concentration of crizotinib resulting in 50% growth inhi-
bition (IC50) was calculated.
Immunoblot Analysis
Cells were washed twice with ice-cold phosphate-buff-
ered saline (PBS) and then lysed in a solution containing 20
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM ethylenedi-
aminetetraacetic acid, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and
leupeptin (1 g/ml). The protein concentration of cell lysates
was determined with a BCA protein assay kit (Thermo
Fischer Scientific, Waltham, MA), and equal amounts of
lysate protein were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on a 7.5 or 12% gel
(Bio-Rad, Hercules, CA). The separated proteins were trans-
ferred to a nitrocellulose membrane, which was then incu-
bated with Blocking One solution (Nacalai Tesque, Kyoto,
Japan) for 20 minutes at room temperature before incubation
overnight at 4°C with primary antibodies. Rabbit polyclonal
antibodies to phosphorylated humanMET (pY1234/pY1235), to
AKT, to phosphorylated AKT, to poly(ADP-ribose) polymerase
(PARP), to BIM, to Bcl-xL, to Mcl-1, and to XIAP were
obtained from Cell Signaling Technology (Danvers, MA);
those to extracellular signal-regulated kinase (ERK) and to
phosphorylated ERK were from Santa Cruz Biotechnology
(Santa Cruz, CA); those to MET were from Zymed (South
San Francisco, CA); those to survivin were from Novus
(Littleton, CO); and those to -actin were from Sigma. All
antibodies were used at a 1:1000 dilution, with the exception
of those to -actin (1:200). The membrane was then washed
with PBS containing 0.05% Tween 20 before incubation for
1 hour at room temperature with horseradish peroxidase-conju-
gated goat antibodies to rabbit immunoglobulin G (Sigma).
Immune complexes were finally detected with chemilumines-
cence reagents (GE Healthcare, Little Chalfont, UK).
Annexin V Binding Assay
Binding of annexin V to cells was measured with the use
of an Annexin-V-FLUOS Staining Kit (Roche, Basel, Switzer-
land). Cells were harvested by exposure to trypsin ethylenedi-
aminetetraacetic acid, washed with PBS, and centrifuged at 200
g for 5 minutes. The cell pellets were resuspended in 100 l of
Annexin-V-FLUOS labeling solution, incubated for 10 to 15
minutes at 15 to 25°C, and then analyzed for fluorescence with
a flow cytometer (FACSCalibur) and Cell Quest software (Bec-
ton Dickinson, Franklin Lakes, NJ).
Gene Silencing
Cells were plated at 50 to 60% confluence in six-well
plates or 25-cm2 flasks and then incubated for 24 hours before
transient transfection for the indicated times with small in-
terfering RNAs (siRNAs) mixed with the Lipofectamine
reagent (Invitrogen, Carlsbad, CA). The siRNAs specific for
MET (MET-1, 5-ACAAGAUCGUCAACAAAAA-3; MET-2,
5-CUACAGAAAUGGUUUCAAA-3) or BIM (BIM-1, 5-GG
AGGGUAUUUUUGAAUAA-3; BIM-2, 5-AGGAGGGUA
UUUUUGAAUA-3) messenger RNAs (mRNAs); and nonspe-
cific (control) siRNAs were obtained from Nippon EGT
(Toyama, Japan). The data presented for the effects of BIM
depletion were obtained with the BIM-1 siRNA, but similar
results were obtained with the BIM-2 siRNA.
Forced Expression of Survivin
The pQCXIH-survivin vector was constructed as de-
scribed previously.16 The expression vector was introduced
into EBC-1 or H1993 cells by transfection for 48 hours with
the use of the Lipofectamine 2000 reagent (Invitrogen).
Growth Inhibition Assay In Vivo
Tumor cells (5  106) were injected subcutaneously
into the axilla of 5- to 6-week-old male athymic nude mice.
Treatment was initiated when tumors in each group achieved
an average volume of 200 or 600 mm3. Treatment groups
(n  5 mice each) consisted of control and crizotinib (25 or
50 mg/kg of body weight). Crizotinib was administered by
oral gavage daily for 28 days; control animals received a
0.5% (wt/vol) aqueous solution of hydroxypropylmethylcel-
lulose as vehicle. Tumor volume was determined from caliper
measurements of tumor length (L) and width (W) according to
the formula LW2/2. Both tumor size and body weight were
measured twice per week. The in vivo experiments were
approved by the appropriate ethics committee.
Statistical Analysis
Unless indicated otherwise, quantitative data are presented
as means  SE from three independent experiments and were
analyzed with the unpaired two-tailed Student’s t test. A p value
of less than 0.05 was considered statistically significant.
RESULTS
Crizotinib Inhibits the Proliferation of Lung
Cancer Cells with MET Amplification
We first examined the effect of the MET-TKI crizotinib
on the proliferation in vitro of lung cancer cells positive or
negative for MET amplification. Both of two cell lines with
MET amplification, EBC-1 and H1993, were sensitive to
crizotinib, with IC50 values of10 nM (Table 1). In contrast,
crizotinib did not substantially inhibit the proliferation of
lung cancer cells with a MET mutation (H2122, H1437, and
H596), with an EGFR mutation (PC9 and HCC827) or
without such gene amplification or mutation (A549 and
H1299) (Table 1). These data suggested that crizotinib has a
marked antiproliferative effect in lung cancer cells with MET
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amplification but not in those without MET amplification,
including those with a MET mutation.
Effects of Crizotinib on Downstream Signaling
of MET and on Apoptosis in Lung Cancer Cells
with or without MET Amplification
We next examined the effects of crizotinib on phos-
phorylation of AKT and ERK in lung cancer cell lines.
Crizotinib markedly inhibited the phosphorylation of AKT
and ERK and that of MET in cells with MET amplification
(Figure 1A). Lung cancer cells with a MET mutation mani-
fested a low level of MET phosphorylation that was com-
pletely inhibited by crizotinib, whereas this agent had little
effect on the phosphorylation of AKT or ERK in these cells
(Figure 1A). In addition, crizotinib did not inhibit AKT or
ERK phosphorylation in lung cancer cells with an EGFR
mutation or in those without amplification of MET or muta-
tion of MET or EGFR (Figure 1A). We further investigated
the effect of crizotinib on apoptosis in lung cancer cells. An
annexin V binding assay revealed that crizotinib induced a
substantial level of apoptosis in MET amplification-positive
cells but was largely without effect in the other cell lines
studied (Figure 1B). Consistent with these results, immuno-
blot analysis showed that crizotinib triggered the generation
of the cleaved form of PARP in cells with MET amplification
but not in those with a MET mutation and in those without
amplification or mutation of MET (Figure 1C, data not
shown). These data thus suggested that crizotinib inhibits the
phosphorylation of AKT and ERK, resulting in induction of
apoptosis, in lung cancer cells with MET amplification,
whereas such effects were not observed in cells without MET
amplification, including those with a MET mutation.
Effects of Depletion of MET in Lung Cancer
Cells with MET Amplification or a MET
Mutation
To verify that the antitumor action of crizotinib in MET
amplification-positive lung cancer cells is indeed mediated by
MET inhibition rather than by nonspecific inhibition of other
kinases, we transfected lung cancer cells with two indepen-
dent siRNAs specific for MET mRNA. Transfection with
each MET siRNA resulted in a marked decrease in the
expression of MET in both cells with MET amplification and
those with a MET mutation (Figure 2A). Transfection of MET
amplification-positive cells with the MET siRNAs also re-
sulted in pronounced inhibition of AKT and ERK phosphor-
ylation, whereas transfection of MET mutation-positive cells
had little such effect (Figure 2A). Depletion of MET mark-
edly increased the proportion of apoptotic cells (Figure 2B)
and induced generation of the cleaved form of PARP (Figure
2C) in cells with MET amplification but not in those with a
MET mutation. These data thus indicated that the antitumor
action of crizotinib in lung cancer cells is mediated by
inhibition of MET, and they also suggested that the survival
of lung cancer cells with a MET mutation is not predomi-
nantly dependent on MET signaling.
Effects of Crizotinib on the Expression of
Apoptosis-Related Proteins in MET
Amplification-Positive Lung Cancer Cells
Given that crizotinib induced apoptosis in MET ampli-
fication-positive lung cancer cells, we examined the effects of
this drug on the expression of apoptosis-related proteins in
such cells. Crizotinib up-regulated the expression of BIM, a
proapoptotic member of the Bcl-2 family of proteins, in both
of the MET amplification-positive cell lines examined,
whereas it had little effect on the expression of other Bcl-2
family members including Mcl-1 and Bcl-xL (Figure 3A).
Furthermore, crizotinib down-regulated the expression of
survivin, a member of the inhibitor of apoptosis protein (IAP)
family, in cells with MET amplification, whereas the expres-
sion of XIAP, another IAP family member, remained unaf-
fected (Figure 3A).
Role of BIM Induction and Survivin Down-
Regulation in Crizotinib-Induced Apoptosis in
Cells with MET Amplification
To investigate further whether the up-regulation of
BIM is related to the induction of apoptosis by crizotinib, we
transfected MET amplification-positive lung cancer cells with
a siRNA specific for BIM mRNA. Transfection with the BIM
siRNA markedly suppressed the up-regulation of BIM by
crizotinib without affecting the down-regulation of survivin
(Figure 3B). The annexin V binding assay revealed that such
transfection resulted in inhibition of crizotinib-induced apo-
ptosis (Figure 3B), indicating that BIM induction contributes
to the proapoptotic effect of crizotinib in lung cancer cells
with MET amplification. We obtained similar results with a
second siRNA targeted to a different sequence within BIM
mRNA (data not shown). Given that crizotinib induced
down-regulation of survivin and up-regulation of BIM, we
next examined the role of survivin down-regulation in crizo-
tinib-induced apoptosis. Transfection of MET amplification-
positive cells with an expression vector for human survivin
resulted in inhibition of the crizotinib-induced down-regula-
tion of survivin (Figure 3C). Such overexpression of survivin
also inhibited the induction of apoptosis by crizotinib (Figure
3C), indicating that down-regulation of survivin by crizotinib
TABLE 1. IC50 Values of Crizotinib for Inhibition of the
Growth of NSCLC Cells In Vitro
MET and EGFR Status Cell Line
Crizotinib
IC50 (nM)
MET amplification () EBC-1 5
H1993 10
MET amplification ()
MET mutation () H2122 472
H1437 1284
H596 752
EGFR mutation () A549 646
H1299 642
EGFR mutation () PC9 787
HCC827 767
Data are means of triplicates from representative experiments that were repeated a
total of three times.
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
Tanizaki et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1626
contributes to the proapoptotic effect of this agent in lung
cancer cells with MET amplification. Together, these data
thus suggested that the induction of apoptosis by crizotinib in
lung cancer cells with MET amplification is mediated, at least
in part, by BIM up-regulation and survivin down-regulation.
Effect of Crizotinib on the Growth of Lung
Cancer Cells In Vivo
To determine whether the antitumor action of crizotinib
observed in vitro might also be apparent in vivo, we injected
EBC-1 cells (positive for MET amplification), H1437 cells
(positive for a MET mutation), or A549 cells (negative for
MET amplification and mutation) into nude mice to elicit the
formation of solid tumors. After tumor formation, the mice
were treated with vehicle (control) or crizotinib at a daily
dose of 25 or 50 mg/kg by oral gavage for 4 weeks. Crizotinib
at either dose eradicated tumors in mice injected with EBC-1
cells (Figure 4A). In contrast, tumors in mice injected with
H1437 or A549 cells were not affected by crizotinib treat-
ment even at the dose of 50 mg/kg/d (Figures 4B, C).
Treatment with crizotinib at either dose was well tolerated by
the mice, with no signs of toxicity or weight loss during
therapy (data not shown). Crizotinib thus exhibited a marked
antitumor effect in lung cancer xenografts positive for MET
amplification, whereas it had little effect on those negative for
MET amplification, including those with a MET mutation,
consistent with our results obtained in vitro.
DISCUSSION
Aberrant activation of PTK signaling pathways contrib-
utes to the development of various types of cancer. Small-
FIGURE 1. Effects of crizotinib on MET, AKT, and extracellular signal-regulated kinase (ERK) phosphorylation and on apopto-
sis in lung cancer cell lines. A, The indicated cell lines were incubated with or without crizotinib (100 nM) for 24 hours, after
which cell lysates were prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms
of MET, AKT, or ERK or to -actin (loading control). B, Cells were incubated for 72 hours with or without crizotinib (100 nM),
after which the number of apoptotic cells was determined by staining with annexin V and propidium iodide followed by flow
cytometry. Data are means  SE from three independent experiments. C, Cells incubated as in (B) were lysed and subjected
to immunoblot analysis with antibodies to poly(ADP-ribose) polymerase (PARP) or to -actin.
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molecule inhibitors that target these activated kinases have
been developed and have shown substantial efficacy in clin-
ical trials. The receptor tyrosine kinase MET is considered
one such potential target in cancer, and several MET-TKIs
are currently undergoing clinical trials in humans. The iden-
tification of patient subgroups that might actually benefit
from treatment with such drugs would be expected to opti-
mize their efficacy. We have now shown that the MET-TKI
crizotinib, which is presently undergoing clinical evaluation,
exerted a marked antitumor action in lung cancer cells with
MET amplification but not in those without this genetic
change, including those with a MET mutation. In lung cancer
cells with MET amplification, inhibition of MET by either
crizotinib or siRNAs specific for MET mRNA resulted in
down-regulation of AKT and ERK signaling and the induc-
tion of apoptosis. We also found that the secretion of hepa-
tocyte growth factor (HGF), a MET ligand, did not differ
substantially between lung cancer cells with or without MET
amplification (see Figure, Supplemental Digital Content 1,
http://links.lww.com/JTO/A98). In addition, exogenous HGF
had little effect on the viability of lung cancer cells with MET
amplification (see Figure, Supplemental Digital Content 1,
http://links.lww.com/JTO/A98). Together, these results sug-
gest that MET amplification itself results in constitutive
activation of MET downstream signaling and that tumors
with MET amplification are dependent on such signaling for
their growth and survival. Targeting of MET signaling by
MET-TKIs is thus a potentially valuable therapeutic strategy
for patients with lung cancer with MET amplification, who
account for 5% of all lung cancer cases.6–8
FIGURE 2. Effects of depletion of MET on signal transduction and apoptosis in lung cancer cells. A, The indicated cell lines
were transfected with nonspecific (control) or MET small interfering RNAs (siRNAs) for 48 hours, after which cell lysates were
prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms of MET, AKT, or ERK or
to -actin. B, Cells were transfected with nonspecific (control) or MET siRNAs for 72 hours, after which the number of apopto-
tic cells was determined by staining with annexin V and propidium iodide followed by flow cytometry. Data are means  SE
from three independent experiments. C, Cells transfected as in B were lysed and subjected to immunoblot analysis with anti-
bodies to poly(ADP-ribose) polymerase (PARP) or to -actin.
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Given that crizotinib showed a proapoptotic effect in
MET amplification-positive lung cancer cells, we further
investigated the mediators of crizotinib-induced apoptosis in
these cells. We found that crizotinib induced up-regulation of
BIM, a key proapoptotic member of the Bcl-2 family of
proteins that initiates apoptosis signaling by binding and
antagonizing the function of prosurvival Bcl-2 family mem-
bers.17 Furthermore, depletion of BIM by RNA interference
resulted in inhibition of crizotinib-induced apoptosis in lung
cancer cells with MET amplification, suggesting that up-
regulation of BIM contributes to the induction of apoptosis by
crizotinib in such cells. We also found that crizotinib induced
down-regulation of survivin, a member of the IAP family that
protects cells against apoptosis by either directly or indirectly
inhibiting the activation of effector caspases.18 Moreover,
forced expression of survivin suppressed the induction of
apoptosis by crizotinib, suggesting that inhibition of survivin
expression plays a key role in the proapoptotic effect of this
agent in lung cancer cells with MET amplification. Our present
data thus suggest that MET inhibitor-induced apoptosis is me-
diated both by up-regulation of BIM and by down-regulation of
survivin in lung cancer cells with MET amplification. We and
others have previously shown that EGFR-TKIs induce the
up-regulation of BIM through inhibition of the MEK-ERK
signaling pathway in lung cancer cells with an EGFR muta-
tion.16,19–21 Furthermore, we recently demonstrated that
EGFR-TKIs induce down-regulation of survivin expression
through inhibition of the phosphoinositide 3-kinase (PI3K)-
AKT signaling pathway and that the MEK-ERK-BIM and
PI3K-AKT-survivin pathways independently contribute to
EGFR-TKI-induced apoptosis in EGFR mutation-positive
lung cancer cells.16 Given that the MET-TKI crizotinib in-
hibited phosphorylation of both ERK and AKT and induced
BIM up-regulation and survivin down-regulation in MET
amplification-positive lung cancer cells, MEK-ERK-BIM and
PI3K-AKT-survivin pathways likely also mediate crizotinib-
induced apoptosis in these cells.
Several MET mutations, including those that affect the
kinase domain or other domains (extracellular semaphorin
and juxtamembrane domains) of the protein, have been iden-
tified in tumors. MET-TKIs have been shown to be active
against MET with mutations in the kinase domain,22 whereas
the relationship between the efficacy of such agents and
nonkinase domain mutants of MET has been unclear. MET
mutations occur in 10% of patients with lung cancer and
they cluster in nonkinase domain regions of MET.10,23 The
NSCLC cell line H2122 harbors the N375S mutation of MET,
which is the most frequent mutation of this gene in lung
cancer. This mutation is localized to the ligand-binding sema-
phorin domain of MET and was found to be associated with
loss of affinity of the receptor for HGF,10 although its bio-
logical consequences remain largely unclear. We have now
shown that crizotinib had little effect on signal transduction
or cell survival in H2122 cells, consistent with the previous
observation that transient expression of the N375S mutant of
MET did not result in an increased susceptibility of the
transfected cells to a MET-TKI compared with that of cells
expressing wild-type MET.10 We also examined the effects of
crizotinib in lung cancer cells (H1437 and H596 cells) with
another MET mutation, deletion of exon 14. Loss of the
juxtamembrane domain encoded by this exon was found to
result in a reduced level of MET ubiquitination and an
increase in the half-life of MET, leading to enhancement of
ligand-dependent cell proliferation.11 Nevertheless, the anti-
tumor effects of MET-TKIs in lung cancers with deletion of
exon 14 of MET have not been well characterized. We have
FIGURE 3. Effects of BIM depletion and forced expression
of survivin on apoptosis induced by crizotinib in lung cancer
cells with MET amplification. A, EBC-1 and H1993 cells were
incubated with or without crizotinib (100 nM) for 48 hours,
after which cell lysates were prepared and subjected to im-
munoblot analysis with antibodies to the indicated proteins.
The position of the band corresponding to BIMEL is indi-
cated. B, Cells were transfected with BIM or nonspecific
small interfering RNAs (siRNAs) for 24 hours and then incu-
bated for 72 hours with or without crizotinib (100 nM). The
cells were then lysed and subjected to immunoblot analysis
with antibodies to the indicated proteins (left panel), or they
were evaluated for apoptosis by staining with annexin V and
propidium iodide followed by flow cytometry (right panel).
C, Cells were transfected with an expression vector for sur-
vivin or with the corresponding empty vector (Mock) for 24
hours, incubated with or without 100 nM crizotinib for 72
hours, and then analyzed as in (B). Quantitative data in (B)
and (C) are means  SE from three independent experi-
ments. *p 	 0.05 for the indicated comparisons.
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now shown that inhibition of MET by crizotinib had no
substantial antitumor effect on lung cancer cells with an exon
14 deletion either in vitro or in vivo. In contrast to its effects
in lung cancer cells with MET amplification, depletion of
MET by RNA interference did not substantially affect the
phosphorylation of AKT or ERK or induce apoptosis in lung
cancer cells with either of the MET mutations studied. Our
present study thus suggests that MET-TKIs may have little
clinical efficacy in patients with lung cancer with a MET
mutation.
Our analysis of the effects of crizotinib on the growth
of lung cancer cells in vivo revealed that this agent had a
pronounced antitumor effect in cells with MET amplification
but not in those with a MET mutation or in those without
amplification or mutation of MET. These in vivo data are
consistent with our results obtained in vitro. In addition to
amplification of MET, the MET pathway is also activated by
HGF stimulation. Although lung cancer cells with MET
mutations did not produce substantial amounts of HGF, we
found that exogenous HGF stimulation tended to enhance the
growth of such cells and that of cells without amplification or
mutation of MET in vitro (see Figure, Supplemental Digital
Content 1, http://links.lww.com/JTO/A98). Furthermore, this
HGF-induced growth enhancement was inhibited by crizo-
tinib. These data suggest that crizotinib may also exert anti-
tumor activity in lung cancer without MET amplification
under conditions of paracrine HGF-induced tumor growth.
Our in vivo observations should, therefore, be interpreted
with caution given the limitation that the local stromal envi-
ronment of subcutaneous xenograft tumors in animals differs,
at least in part, from that of human cancers in situ.
Crizotinib also inhibits oncogenic fusion variants of the
tyrosine kinase ALK in addition to MET.24 We found that
crizotinib markedly inhibited the survival of H3122 lung
cancer cells, which are positive for EML4-ALK, in addition
to that of MET amplification-positive cells (see Figure, Sup-
plemental Digital Content 2, http://links.lww.com/JTO/A99).
Given that crizotinib has recently shown marked therapeutic
efficacy in patients with lung cancer positive for EML4-
ALK,25 this agent may also have substantial clinical activity
and be an attractive therapeutic option for patients with lung
cancer with MET amplification.
In conclusion, our results have shown that crizotinib has
pronounced effects on signal transduction and survival in lung
cancer cells with MET amplification but not in those without
MET amplification, including those with a MET mutation. Fur-
thermore, both BIM induction and survivin down-regulation
were found to mediate the proapoptotic effect of crizotinib in
lung cancer cells withMET amplification. Our observations thus
provide a rationale for clinical evaluation of MET-TKIs in
patients with lung cancer with MET amplification.
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